NCT05390307: OTID

Obesity Treatment to Improve Diabetes

Completed NA Last updated 28 February 2024

What this trial tests

NA trial testing Liraglutide / Semaglutide in Type 1 Diabetes in 60 participants. Completed in 1 January 2024.

Timeline

1 April 2023

Primary endpoint
1 January 2024

1 January 2024

Quick facts

Lead sponsor	Dasman Diabetes Institute
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	60
Start date	1 April 2023
Primary completion	1 January 2024
Estimated completion	1 January 2024
Sites	1 location across Kuwait

Drugs / interventions tested

• Liraglutide / Semaglutide — full drug profile →
• Dapagliflozin (DAPAGLIFLOZIN) — full drug profile →
• Liraglutide or Semaglutide / Dapagliflozin — full drug profile →
• Liraglutide or Semaglutide / Dapagliflozin plus intensive weight loss nutrition — full drug profile →
• Usual care

Conditions studied

• Type 1 Diabetes — all drugs for Type 1 Diabetes →

Sponsor

Dasman Diabetes Institute

Who can join

Adults 21 to 65, any sex, with Type 1 Diabetes. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

As the obesity pandemic continues unabated, one can expect to see an increase in the prevalence of TID/T2D and associated CKD. As a result, death will rise, preceded by an increase in kidney failure, requiring dialysis and renal transplantation. Innovative medical treatment may help prevent chronic kidney disease (CKD) across our healthcare system. The guideline of the American Diabetes Association (ADA) and European Association for the Study of Diabetes (EASD) suggest that patients with obesity, TID/ T2D, and CKD needed either glucagon-like peptide 1 receptor analogs (GLP1-RA) or sodium-glucose cotransport-2 inhibitors (SGLT2i). If neither achieve metabolic control, then the recommendation is to combine both drugs. The evidence base for combining GLP1RA and SGLT2i are not well developed, and hence the impact of the guidelines are limited. This study will provide evidence of discrete metabolic pathways by the GLP1RA/or SGLT2i alone or in combination contributed to metabolic control. The aim of this randomised control trial (RCT) is to test the impact of the combination of GLP1RA/SGLT2i on body weight and kidney damage, in patients with T1DM and CKD. In addition, we will explore associated changes in metabolic pathways with each of the treatments used in the RCT.

Publications & conference data

5 peer-reviewed publications reference this trial (live from Europe PMC):

1. The emergence of obesity in type 1 diabetes.
   Kueh MTW, Chew NWS, Al-Ozairi E, le Roux CW. · · 2024 · cited 57× · PMID 38092958 · DOI 10.1038/s41366-023-01429-8
2. Managing obesity in adults with type 1 diabetes.
   Campos A, Gutierrez RR, Galindo RJ, McCoy RG, et al · · 2025 · cited 5× · PMID 39746549 · DOI 10.1016/j.diabres.2024.111983
3. Obesity Treatments to Improve Type 1 Diabetes (OTID): a randomized controlled trial of the combination of glucagon-like peptide 1 analogues and sodium-glucose cotransporter 2 inhibitors-protocol for Obesity Treatments to Improve Type 1 Diabetes (the OTID trial).
   Al-Ozairi E, Narula K, Miras AD, Taghadom E, et al · · 2024 · cited 4× · PMID 38365744 · DOI 10.1186/s13063-024-07930-3
4. Treatment of the disease of obesity in patients with type 1 diabetes with tirzepatide: a protocol for a randomised controlled trial in a single-centre setting.
   Al Ozairi E, Al Awadhi A, Taghadom E, Al Kandari J, et al · · 2026 · PMID 42097660 · DOI 10.1136/bmjopen-2026-117431
5. Combining glucagon-like peptide 1 analogues with sodium-glucose cotransporter 2 inhibitors to treat patients with type 1 diabetes, BMI > 25 kg/m², and chronic kidney disease - A randomised, controlled pilot study.
   Al Ozairi E, Taghadom E, Irshad M, Yousef AA, et al · · 2026 · PMID 41435968 · DOI 10.1016/j.diabres.2025.113066